m6A-centered Disease Response Information

General Information of the Disease (ID: M6ADIS0137)
Name
Atopic eczema
ICD
ICD-11: EA80
Full List of Target Gene(s) of This m6A-centered Disease Response
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1)
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary circRNA hsa_circ_0004287 was upregulated in peripheral blood mononuclear cells of both AD and psoriasis patients. hsa_circ_0004287 reduced the stability of its host gene Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) by competitively binding to IGF2BP3 with MALAT1 in an N6-methyladenosine (m6A)-dependent manner.
Responsed Disease Atopic eczema [ICD-11: EA80]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response MAPK signaling pathway hsa04010
Ubiquitin mediated proteolysis hsa04120
Cell Process Inflammation
Proteasome pathway degradation
In-vitro Model RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
In-vivo Model IMQ-induced psoriatic model was constructed by applying 10 mg per ear 5% IMQ for 8 consecutive days, and 6 ug macrophage-specific control or hsa_circ_0004287 plasmid was topically applied every 2 days (5 mice per group per experiment).
hsa_circ_0004287
 Target Info 
In total 1 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [1]
Response Summary hsa_circ_0004287 was upregulated in peripheral blood mononuclear cells of both AD and psoriasis patients. hsa_circ_0004287 reduced the stability of its host gene metastasis associated lung adenocarcinoma transcript 1 (MALAT1) by competitively binding to IGF2BP3 with MALAT1 in an N6-methyladenosine (m6A)-dependent manner.
Responsed Disease Atopic eczema [ICD-11: EA80]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) READER
 Regulator Info 
Target Regulation Up regulation
Pathway Response MAPK signaling pathway hsa04010
Ubiquitin mediated proteolysis hsa04120
Cell Process Inflammation
Proteasome pathway degradation
In-vitro Model RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
In-vivo Model IMQ-induced psoriatic model was constructed by applying 10 mg per ear 5% IMQ for 8 consecutive days, and 6 ug macrophage-specific control or hsa_circ_0004287 plasmid was topically applied every 2 days (5 mice per group per experiment).
References
Ref 1 Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N(6)-methyladenosine-dependent manner in atopic dermatitis and psoriasis. J Allergy Clin Immunol. 2022 Jun;149(6):2021-2033. doi: 10.1016/j.jaci.2021.11.024. Epub 2021 Dec 23.